(RTTNews) - EDAP TMS SA (EDAP) announced Monday that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep ...

The FDA has approved Transcranial Magnetic Stimulation (TMS), a non-drug, magnetic pulse device, for use in teens as young as 15 to treat severe depression. TMS is now an option for adolescents who ...

While devices that stimulate the brain invasively have generally been available since 2002, and devices that do so non-invasively have been available since 2013, in recent years, the U.S. Food and ...

Please provide your email address to receive an email when new articles are posted on . The Apollo TMS device was previously FDA cleared for treating MDD in adults. TMS offers a non-pharmacologic ...

Munich, Germany; Atlanta, Georgia - September 10, 2025 – neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance, today announced it has ...

Moment of Clarity has released a new resource titled “Transcranial Magnetic Stimulation (TMS) Success Rate“, now available online. The article explores the effectiveness of TMS therapy in treating ...

BOSTON, Oct. 13, 2025 /PRNewswire/ -- Zeta Surgical today announced that its Zeta TMS Navigation System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is ...

The first OnQ Prostate-assisted Focal One® Robotic HIFU procedure was successfully performed at UCSF, improving prostate cancer treatment precision. Cortechs.ai and EDAP TMS have announced the ...